Heat Biologics, Inc. (HTBX): Price and Financial Metrics


Heat Biologics, Inc. (HTBX): $6.71

0.06 (+0.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HTBX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

HTBX Stock Summary

  • HTBX's price/sales ratio is 57.32; that's higher than the P/S ratio of 94.95% of US stocks.
  • In terms of volatility of its share price, HTBX is more volatile than 97.55% of stocks we're observing.
  • Heat Biologics Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -71.8%, greater than the shareholder yield of only 3.47% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Heat Biologics Inc are SITM, PI, GWRE, UTHR, and CLGN.
  • Visit HTBX's SEC page to see the company's official filings. To visit the company's web site, go to www.heatbio.com.

HTBX Stock Price Chart Interactive Chart >

Price chart for HTBX

HTBX Price/Volume Stats

Current price $6.71 52-week high $30.10
Prev. close $6.65 52-week low $3.50
Day low $6.56 Volume 258,700
Day high $6.91 Avg. volume 2,099,281
50-day MA $8.12 Dividend yield N/A
200-day MA $8.77 Market Cap 170.50M

Heat Biologics, Inc. (HTBX) Company Bio


Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.


HTBX Latest News Stream


Event/Time News Detail
Loading, please wait...

HTBX Latest Social Stream


Loading social stream, please wait...

View Full HTBX Social Stream

Latest HTBX News From Around the Web

Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.

Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021

DURHAM, NC / ACCESSWIRE / April 12, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today reported that promising new preclinical data of PTX-35 is presented at the AACR Annual Meeting 2021.

Yahoo | April 12, 2021

Heat Biologics Provides Year-End Business Update

DURHAM, NC / ACCESSWIRE / March 25, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provided financial, clinical and operational updates for the year ended December 31, 2020.

Yahoo | March 25, 2021

Heat Biologics Earnings Report: Here’s what to expect from Stock market Insights & financial analysis

Heat Biologics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 22, 2021

Heat Biologics Wall street estimates Earnings report Stock market Insights & financial analysis

Heat Biologics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…

Stock Market Daily | March 15, 2021

Covid-19 Product Market With Top Key Players like 3M, Cardinal Health, Kimberly- Clark, Johnson and Johnson, Sanofi, Ansell, Abbott Laboratories, BD, Henry Schein, Heat Biologics

An off-the-shelf report on Covid-19 Product Market which has been compiled after an in-depth analysis of the market trends prevailing across five geographies (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). Various segments of the market such as

OpenPR | March 4, 2021

Read More 'HTBX' Stories Here

HTBX Price Returns

1-mo -11.71%
3-mo -2.61%
6-mo -19.45%
1-year 66.51%
3-year -14.41%
5-year -85.90%
YTD 25.19%
2020 61.20%
2019 -51.53%
2018 -74.41%
2017 -55.47%
2016 -64.75%

Continue Researching HTBX

Here are a few links from around the web to help you further your research on Heat Biologics Inc's stock as an investment opportunity:

Heat Biologics Inc (HTBX) Stock Price | Nasdaq
Heat Biologics Inc (HTBX) Stock Quote, History and News - Yahoo Finance
Heat Biologics Inc (HTBX) Stock Price and Basic Information | MarketWatch

Page generated in 0.9718 seconds.